Journal of Clinical and Experimental Hematopathology

Scope & Guideline

Empowering Researchers with Open Access Discoveries.

Introduction

Welcome to the Journal of Clinical and Experimental Hematopathology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Journal of Clinical and Experimental Hematopathology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1346-4280
PublisherJAPANESE SOC LYMPHORETICULAR TISSUE RESEARCH
Support Open AccessYes
CountryJapan
TypeJournal
Convergefrom 2006 to 2016, from 2019 to 2024
AbbreviationJ CLIN EXP HEMATOP / J. Clin. Exp. Hematop.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNAGOYA UNIV GRAD SCH MEDICINE, HIGH-TECHNOLOGY APPLICATION MEDICINE, CLINICAL PATHOPHYSI, NAGOYA 466-8550, JAPAN

Aims and Scopes

The Journal of Clinical and Experimental Hematopathology primarily focuses on advancing the understanding and treatment of hematologic malignancies. It serves as a platform for sharing innovative research findings, clinical experiences, and insights into the pathology of blood-related disorders, particularly lymphomas and leukemias.
  1. Hematologic Malignancies Research:
    The journal emphasizes research on various hematologic malignancies, including lymphomas, leukemias, and plasma cell disorders. It covers both clinical and experimental studies that contribute to the understanding of these diseases.
  2. Clinical Case Reports and Reviews:
    A significant portion of the journal includes case reports and literature reviews that provide insights into rare and complex cases, thereby enhancing clinical knowledge and guiding treatment strategies.
  3. Pathological Insights and Diagnostics:
    The journal highlights the importance of pathology in diagnosing hematologic disorders. It publishes studies focusing on histopathological evaluations, immunohistochemistry, and molecular techniques that assist in accurate diagnosis.
  4. Therapeutic Advances and Clinical Trials:
    Research on new therapeutic approaches, including novel drug treatments and clinical trial outcomes, is a core focus. The journal aims to disseminate findings that can influence treatment protocols and improve patient outcomes.
  5. Tumor Microenvironment and Immune Response:
    There is a growing emphasis on the role of the tumor microenvironment and immune interactions in hematologic diseases. The journal explores how these factors affect disease progression and treatment responses.
The Journal of Clinical and Experimental Hematopathology has been evolving, with several themes emerging as increasingly prominent in recent publications. This section outlines the trending and emerging scopes that reflect the current interests and advancements in the field.
  1. Precision Medicine and Targeted Therapies:
    There is a significant trend towards research focused on precision medicine and targeted therapies for hematologic malignancies. This includes studies on specific genetic mutations, biomarkers, and tailored treatment approaches that enhance efficacy and minimize toxicity.
  2. Immunotherapy and CAR T-cell Therapy:
    Immunotherapy, particularly CAR T-cell therapy, is gaining prominence in the journal's publications. Research exploring the mechanisms, efficacy, and safety of these therapies is increasingly relevant as they become standard treatment options for various hematologic cancers.
  3. Tumor Microenvironment Studies:
    Emerging themes related to the tumor microenvironment, including the interplay between tumor cells and immune cells, are becoming a focal point. This research is crucial for understanding disease progression and developing new therapeutic strategies.
  4. Patient-Centered Outcomes and Quality of Life:
    Research that addresses patient perspectives, treatment satisfaction, and quality of life is on the rise. This trend highlights the importance of incorporating patient-reported outcomes into clinical practice and research.
  5. Novel Biomarkers for Diagnosis and Prognosis:
    The discovery and validation of novel biomarkers for the diagnosis and prognosis of hematologic malignancies are increasingly featured. Such studies are essential for improving diagnostic accuracy and tailoring treatment strategies.

Declining or Waning

While the Journal of Clinical and Experimental Hematopathology maintains a broad focus on hematologic disorders, certain themes have begun to decline in prominence. This section highlights these waning scopes based on recent publication trends.
  1. Basic Laboratory Techniques:
    There appears to be a declining focus on basic laboratory techniques and methodologies compared to more advanced and specialized studies. Research that centers solely on traditional laboratory methods without novel insights or applications has become less common.
  2. Generalized Reviews without Novel Insights:
    The journal has seen a decrease in generalized review articles that do not provide new perspectives or significant updates on existing knowledge. There is a trend towards more focused reviews that address specific questions or emerging issues.
  3. Older Treatment Protocols:
    Research centered around older treatment protocols, especially those that have been largely replaced by newer regimens or therapies, is becoming less frequent. The journal is shifting towards studies that investigate contemporary treatment strategies and their outcomes.
  4. Epidemiological Studies without Clinical Relevance:
    Epidemiological studies that lack direct clinical relevance or applicability to current treatment practices are being published less frequently. The focus is moving towards studies that bridge the gap between epidemiology and clinical application.

Similar Journals

AMERICAN JOURNAL OF DERMATOPATHOLOGY

Fostering Insights for Better Patient Care
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0193-1091Frequency: 12 issues/year

AMERICAN JOURNAL OF DERMATOPATHOLOGY, published by Lippincott Williams & Wilkins, is an essential resource for professionals and researchers engaged in the fields of dermatology, pathology, and forensic medicine. Established in 1979, the journal aims to disseminate cutting-edge research and advancements pertaining to the microscopic examination of skin disorders. With an esteemed impact factor that positions it well within the Q3 category of dermatology and pathology as of 2023, the journal ranks #81 out of 142 in dermatology and #130 out of 208 in pathology according to Scopus. Although it does not currently offer open access options, the journal provides valuable insights and substantial contributions to the understanding of dermatopathology, making it a vital tool for academics, clinicians, and students seeking to stay abreast of the latest findings and practices in the field. Its commitment to high-quality research continues to foster a deeper understanding of skin diseases, enhancing patient care and scientific inquiry alike.

Blood Cancer Discovery

Catalyzing Change in Cancer Research Landscapes
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

International Journal of Clinical and Experimental Pathology

Fostering Collaboration in the World of Pathology
Publisher: E-CENTURY PUBLISHING CORPISSN: 1936-2625Frequency: 12 issues/year

International Journal of Clinical and Experimental Pathology, published by E-CENTURY PUBLISHING CORP, serves as a vital resource for professionals in the field of pathology. With its ISSN 1936-2625, the journal has positioned itself within the competitive landscape of medical journals, achieving commendable rankings in Scopus, particularly in the categories of Pathology and Forensic Medicine (Rank #98/185) and Histology (Rank #38/58). Although its coverage in Scopus has been discontinued, the journal’s past contributions from 2009 to 2017 continue to be a touchstone for researchers interested in advancing their understanding of clinical and experimental pathology. The open-access format ensures accessibility to a wide audience, fostering collaboration and education in this essential medical discipline. By bridging clinical research and experimental findings, this journal plays a crucial role in disseminating knowledge and enhancing practices within pathology, making it an indispensable tool for researchers, professionals, and students alike.

Hematology Transfusion and Cell Therapy

Pioneering insights in hematology and transfusion care.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Hematology

Empowering Research: Your Gateway to Hematology Excellence
Publisher: TAYLOR & FRANCIS LTDISSN: 1024-5332Frequency: 1 issue/year

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

SEMINARS IN HEMATOLOGY

Shaping the Future of Blood Health Through Scholarly Discourse.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0037-1963Frequency: 4 issues/year

SEMINARS IN HEMATOLOGY, published by W B SAUNDERS CO-ELSEVIER INC, stands as a premier academic journal dedicated to the field of hematology. Established in 1964, this journal has built a robust reputation over its nearly six-decade history, now recognized as a Q1 journal in Hematology with an impressive impact factor reflective of its high relevance and citation frequency within the academic community. Residents and scholars can access meticulously curated articles that address innovative research, clinical practices, and advancements in the understanding of blood disorders and treatment methodologies. The journal, ranked #36 out of 137 in the Scopus Medicine Hematology category, showcases cutting-edge research, ensuring its contributions are crucial for professionals, researchers, and students striving to stay at the forefront of the hematology field. Although not an Open Access journal, SEMINARS IN HEMATOLOGY continues to unite a global audience dedicated to advancing the science and clinical practices in hematology.

PATHOLOGY INTERNATIONAL

Navigating the Evolving Landscape of Pathological Insights
Publisher: WILEYISSN: 1320-5463Frequency: 12 issues/year

PATHOLOGY INTERNATIONAL, published by WILEY, stands as a distinguished journal in the field of pathology and forensic medicine, serving as an essential resource for researchers, clinicians, and students alike. With its ISSN 1320-5463 and E-ISSN 1440-1827, PATHOLOGY INTERNATIONAL has established itself since its inception in 1951, navigating through an evolving landscape in medical science with insights and breakthroughs up to 2024. It holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pathology and Forensic Medicine categories, indicating its robust influence and quality within these fields, as evidenced by its placement in the 70th percentile of Scopus rankings. While currently not an open-access journal, it provides access options that ensure valuable research remains available to the academic community. PATHOLOGY INTERNATIONAL commits to advancing the discipline through pioneering research articles, comprehensive reviews, and expert opinions that push the boundaries of understanding in pathology, thereby supporting the enhancement of diagnostic and therapeutic practices.

International Journal of Laboratory Hematology

Pioneering insights in hematology for a healthier tomorrow.
Publisher: WILEYISSN: 1751-5521Frequency: 6 issues/year

The International Journal of Laboratory Hematology, published by WILEY, serves as a vital resource in the field of hematology, delivering high-quality research findings and innovations within laboratory practices since its inception in 2007. This journal, accessible under Open Access options, showcases cutting-edge studies that span critical aspects of biochemistry and clinical laboratory methodologies. With a notable impact factor reflected in its Q2 and Q3 rankings across various categories—such as Biochemistry (medical) and Hematology—this journal stands out within the Scopus rankings, positioning itself within the 60th and 59th percentiles of its respective fields. Situated in the United Kingdom, the journal's objectives lie in disseminating pivotal research that enhances our understanding of hematological disorders and laboratory techniques, making it an essential tool for researchers, professionals, and students alike who are committed to advancing the science of laboratory hematology and its applications.

Indian Journal of Pathology and Microbiology

Championing Open Access to Scientific Excellence
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0377-4929Frequency: 4 issues/year

Indian Journal of Pathology and Microbiology, published by Wolters Kluwer Medknow Publications, is a distinguished open-access journal that has been fostering knowledge dissemination in the fields of pathology and microbiology since 2008. With an ISSN of 0377-4929 and E-ISSN 0974-5130, this journal serves as a critical resource for researchers and practitioners committed to advancing their understanding of medical sciences in India and beyond. Spanning decades of valuable research contributions since its establishment in 1972, it provides a platform for peer-reviewed articles that explore current trends and innovations in medicinal pathology and microbiological studies. Although it holds a Q4 ranking in categories such as medicine and microbiology, it maintains a notable Q3 classification in pathology and forensic medicine, highlighting its relevance to contemporary scientific discussions. Accessible freely to a global audience, the journal plays a pivotal role in enhancing scholarly communication and collaboration, making it an indispensable tool for students, professionals, and researchers alike aiming to contribute to this evolving discipline.

BLOOD

Elevating Excellence in Hematological Studies.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.